Skip to main content
. 2016 Sep;186(9):2404–2416. doi: 10.1016/j.ajpath.2016.04.017

Figure 2.

Figure 2

Colonic IL-13 and IL-17 expression increases in FVB RELMβ−/− mice. Colon IL-13 (A), IL-17 (B), and interferon (IFN)γ (C) mRNA levels during the azoxymethane/dextran sodium sulfate (DSS) treatment time course (baseline, day 7, 28, and 85) in 11- to 12-week-old female FVB RELMβ−/− mice and littermate controls. D: Serum IL-13 levels in response to 7 days of DSS treatment in 9-month-old male FVB RELMβ−/− mice and littermate controls. N = 4 to 7 per genotype and time point (A–C); N = 3 knockout (D); N = 6 wild type (D). ∗P < 0.05, ∗∗P < 0.01 for the difference between the genotypes (there is also a trend for a difference in IL-13 expression between genotypes at baseline, P = 0.08); †P < 0.05 for the difference from baseline within a genotype (there is also a trend for a difference in IFNγ expression between baseline and day 29 within wild-type mice, P = 0.06). WT, wild type.